The FINANCIAL — Roche announced on June 23 that the US Food and Drug Administration (FDA) approved Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for ...

Rituxan was administered at a dose of 1000 mg via IV infusion on day 1 and 15, with a repeat administration on days 168 and 182. MMF was administered at a dose of 2 grams orally daily from day 1 to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the ...

There were nearly identical response rates and toxicity with subcutaneous administration of Rituxan (rituximab) and IV administration of the drug to treat follicular lymphoma in the first-line setting ...

Truxima is a biosimilar version of the brand-name drug Rituxan. Biosimilars tend to be less expensive than their brand-name versions. Doctors prescribe Truxima to treat conditions such as rheumatoid ...

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...

The FDA has approved intravenous Rituxan for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children 2 years and older in combination with glucocorticosteroids. This ...

September 11, 2008 — The safety labeling for rituximab intravenous infusion (Rituxan, Genentech, Inc, comarketed with Biogen Idec, Inc) has been updated to reflect a fatal case of progressive ...

NEW ORLEANS -- In a randomized comparison, rituximab (Rituxan) proved non-inferior to cyclosporine for the treatment of idiopathic membranous nephropathy, a researcher reported here. Preliminary ...

December 19, 2006 — The US Food and Drug Administration (FDA) is warning healthcare professionals regarding the risk for progressive multifocal leukoencephalopathy (PML) in patients receiving ...

The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 ...